Clindac A 1% Topical Solution
Prescription required
Highlights
composition with strength
Clindamycin (1%w/v)
description
Effective topical acne treatment, reduces acne-causing bacteria, minimizes skin inflammation, prevents new pimples
key benefits
Treatment of Bacterial Infections and Treatment of Acne
side effects
Skin rash, Stomach pain, Nausea, Vomiting and Diarrhea
how to use
Use this medication as directed by your doctor
alcohol interaction
Unsafe
pregnancy interaction
Unsafe
lactation interaction
Consult Your Doctor
driving interaction
Safe
kidney interaction
Caution
liver interaction
Safe If Prescribed
Information
disclaimer
The contents and images displayed on this Platform are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a registered medical practitioner with any questions you may have regarding a medical condition or the use of any product. Do not disregard professional medical advice or delay seeking it because of something you have read on this Platform.We intend to support, not replace, the doctor-patient relationship.
While we make every effort to ensure the information provided is accurate and up-to-date, we strongly recommend reviewing product labels, batch numbers, manufacturing and packaging details, as well as any warnings and usage instructions before using or consuming any product.
customer care details
In case of any issue, contact us
E-mail address: support@zeptonow.com
Seller Name
Geddit Convenience Private Limited
Seller Address
Geddit Convenience Private Limited, Unit 508, Sakti Statesman, 5th floor, Green Glen Layout, No.37/301/34/1, SY.NO.34, Ibblur Village, Begur Hobli, Bangalore, Karnataka-560103
Pharmacy License No.
KA-B61-274705, KA-B61-274706
Manufacturer or Marketer Name
Alkem Laboratories Limited
Manufacturer or Marketer Address
Devashish Building, Alkem House, Senapati Bapat Road, Lower Parel, Mumbai - 400 013
Country of Origin
India
Shelf Life
24 months
Expires on or after
March 2027
